As Horizon ties up the loose ends for its $28 billion sale to Amgen, a drug it picked up from a previous acquisition of its own is delivering a mid-stage win.

Horizon had already declared Phase II success for dazodalibep among one group of patients with Sjögren’s syndrome back in September. Now, it is announcing that the drug also met the primary endpoint for the second patient population in the trial, setting up a 2023 launch for a Phase III program it will work with the FDA to design. That timeline is ahead of expectations, the company added.

Read more on Endpoints News